Abstract
The epithelial sodium channel/degenerin (ENaC/deg) family of ion channels is formed by a large number of genes with variable tissue expression patterns and physiological roles. ENaC is a non-voltage gated, constitutively active channel highly selective for sodium. ENaC is formed by three homologous subunits, α, β and γ, and a fourth subunit (δ) has been found in human and monkeys that can substitute α to form functional channels. The best-characterized role of ENaC is to serve as a rate-limiting step in transepithelial sodium reabsorption in the distal part of the kidney tubule and other tight epithelia. However, ENaC subunits are also found in the peripheral and central nervous system, where their functional roles are only beginning to be understood. In this review, we mainly focus on the putative pathophysiological roles of ENaC channels in the central nervous system and their potential value as drug targets in neurodegenerative disorders and the central control of blood pressure.
Keywords: ASIC, amiloride, degenerins, delta subunit, ENaC, neuroprotection.
Current Molecular Pharmacology
Title:ENaC in the Brain - Future Perspectives and Pharmacological Implications
Volume: 6
Author(s): Teresa Giraldez, Jaime Dominguez and Diego Alvarez de la Rosa
Affiliation:
Keywords: ASIC, amiloride, degenerins, delta subunit, ENaC, neuroprotection.
Abstract: The epithelial sodium channel/degenerin (ENaC/deg) family of ion channels is formed by a large number of genes with variable tissue expression patterns and physiological roles. ENaC is a non-voltage gated, constitutively active channel highly selective for sodium. ENaC is formed by three homologous subunits, α, β and γ, and a fourth subunit (δ) has been found in human and monkeys that can substitute α to form functional channels. The best-characterized role of ENaC is to serve as a rate-limiting step in transepithelial sodium reabsorption in the distal part of the kidney tubule and other tight epithelia. However, ENaC subunits are also found in the peripheral and central nervous system, where their functional roles are only beginning to be understood. In this review, we mainly focus on the putative pathophysiological roles of ENaC channels in the central nervous system and their potential value as drug targets in neurodegenerative disorders and the central control of blood pressure.
Export Options
About this article
Cite this article as:
Giraldez Teresa, Dominguez Jaime and Rosa Diego Alvarez de la, ENaC in the Brain - Future Perspectives and Pharmacological Implications, Current Molecular Pharmacology 2013; 6 (1) . https://dx.doi.org/10.2174/1874467211306010006
DOI https://dx.doi.org/10.2174/1874467211306010006 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neuroprotection & Mechanism of Ethanol in Stroke and Traumatic Brain Injury Therapy: New Prospects for an Ancient Drug
Current Drug Targets Regulation of HIF-1α at the Transcriptional Level
Current Pharmaceutical Design MicroRNA Targeting as a Therapeutic Strategy Against Glioma
Current Molecular Medicine Recent Trend for EGFR-Based and ALK-Based Targets: A Patent Analysis
Recent Patents on Anti-Cancer Drug Discovery The Role of IRE1 Signaling in the Central Nervous System Diseases
Current Neuropharmacology Genes Involved in Apoptosis Regulation: Implications for Cancer Therapy
Current Genomics Impact of Hybrid-polar Histone Deacetylase Inhibitor m-Carboxycinnamic Acid bis-Hydroxyamide on Human Pancreatic Adenocarcinoma Cells
Anti-Cancer Agents in Medicinal Chemistry Polypharmacological Properties and Therapeutic Potential of β-Caryophyllene: A Dietary Phytocannabinoid of Pharmaceutical Promise
Current Pharmaceutical Design MicroRNA-136 Promotes Vascular Muscle Cell Proliferation Through the ERK1/2 Pathway by Targeting PPP2R2A in Atherosclerosis
Current Vascular Pharmacology Cancer Gene Therapy with Tissue Inhibitors of Metalloproteinases (TIMPs)
Current Gene Therapy Protection Mechanisms Against Aβ42 Aggregation
Current Alzheimer Research Angiogenesis as a Therapeutic Target in Arthritis: Lessons from Oncology
Current Pharmaceutical Design Cancer Therapy: Targeting Cell Cycle Regulators
Anti-Cancer Agents in Medicinal Chemistry The Current WHO Classification of Tumours of the Central Nervous System: Histopathology and Additional Diagnostic Methods
Current Medical Imaging Sugars that Glow in the Dark: Fluorescent Tagged Glucose Bioprobes and their Facilitation of the Drug Discovery Process
Current Medicinal Chemistry [177Lu]-DOTA0-Tyr3-Octreotate: A Potential Targeted Radiotherapeutic for the Treatment of Medulloblastoma
Current Radiopharmaceuticals Suramin: Clinical Uses and Structure-Activity Relationships
Mini-Reviews in Medicinal Chemistry VEGF in Tumor Progression and Targeted Therapy
Current Cancer Drug Targets Focal Adhesion Kinase as a Cancer Therapy Target
Anti-Cancer Agents in Medicinal Chemistry Non-histone Methylation of SET7/9 and its Biological Functions
Recent Patents on Anti-Cancer Drug Discovery